Order | Nanologica

Nanologica Delivers NLAB SIV™ to a Customer in Asia to a Value of over MSEK 4

12 February, 2024

Nanologica has made the first delivery of the company's non-silica-based purification media NLAB Siv™ to a customer in Asia against an order received in November. The value amounts to over MSEK 4. NLAB Siv™ is a non-silica-based purification media that has been developed together with a customer who sells a number of pharmaceutical products. NLAB Siv™ is used for purification through preparative chromatography and the customer has expressed a desire to replace the purification media they

Nanologica levererar NLAB SIV™ till kund i Asien till ett värde om drygt 4 MSEK

12 February, 2024

Nanologica har gjort den första leveransen av bolagets icke silika-baserade reningsmedia NLAB Siv™ till en kund i Asien mot en order som togs i november. Värdet uppgår till drygt 4 MSEK. NLAB Siv™ är ett icke silikabaserat reningsmedia som har utvecklats tillsammans med en kund som säljer ett flertal läkemedelsprodukter. NLAB Siv™ används för rening genom preparativ kromatografi och kunden har uttryckt önskemål om att ersätta det reningsmedia de idag använder i produktion av ett

Nanologica levererar silika till kund i Kina till ett värde om 930 TSEK

8 January, 2024

Nanologicas kinesiska distributör Yunbo Technology har gjort ytterligare ett avrop mot det avtal som tidigare tecknats avseende leverans av silika till ett värde av 14 MUSD över en sexårsperiod. Detta avrop uppgår till cirka 930 TSEK. Leveransen som nu sker är den fjärde som Nanologica gör sedan bolaget godkände sin silikabaserade media för preparativ kromatografi, NLAB Saga®. Ordern för denna leverans togs under 2022 och är det första avropet mot betalning inom det långsiktiga avtal

Nanologica Delivers Silica to Customer in China to a Value of TSEK 930

8 January, 2024

Nanologica's Chinese distributor Yunbo Technology has made another call-off against the agreement previously signed for the delivery of silica worth USD 14 million over a six-year period. This call-off amounts to approximately SEK 930 thousand. The delivery is the fourth that Nanologica has made since the company approved its silica-based media for preparative chromatography, NLAB Saga®. The order for this delivery was taken in 2022 and is the first call-off against payment within the long-term

Nanologica levererar silika till kund i Kina

11 December, 2023

Nanologicas kinesiska distributör Yunbo Technologies har gjort ett första avrop mot det avtal som tidigare tecknats avseende leverans av silika till ett värde av 14 MUSD över en sexårsperiod. I samband med att Nanologica startade storskalig produktion av silika 2019 slöts ett leveransavtal med bolagets kinesiska distributör Yunbo Technologies innebärande att Nanologica ska leverera media för preparativ kromatografi till ett värde av ca 14 MUSD över en sexårsperiod. Leveransen som nu sker är ett första

Nanologica Delivers Silica to Customer in China

11 December, 2023

Nanologica's Chinese distributor Yunbo Technologies has made a first call-off against the agreement previously signed for the delivery of silica worth USD 14 million over a six-year period. In connection with Nanologica's start of large-scale production of silica in 2019, a supply agreement was signed with the company's Chinese distributor Yunbo Technologies, whereby Nanologica will deliver media for preparative chromatography to a value of approximately USD 14 million over a six-year period. The delivery that

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.